ArticlePharmaceutical research2025
Predicting Food Effect On Oral Drug Absorption For Solubility-Epithelial Membrane Permeation-Limited Cases With Bile Micelle Solubilization.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment.Pharmaceutics · 2026Article
- The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant).Molecular pharmaceutics · 2026Article
- Physiologically Based Pharmacokinetic (PBPK) Modeling of Oral Drug Absorption for Integrating Nonclinical Data into Human Pharmacokinetic Predictions.The AAPS journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the theoretical and in vitro experimental prediction of food effects on oral drug absorption, focusing on solubility-epithelial membrane permeation-limited cases (SL-E).
methodBosentan, fidaxomicin, pranlukast, and rifaximin were employed as model SL-E drugs. Celecoxib and danazol were employed as solubility-unstirred water layer permeation-limited cases (SL-U) for comparison. Theoretical predictions of food effects were based on the rate-limiting steps of the fraction of a dose absorbed (Fa) (FaRLS) (Fa rate-limiting step). μFLUX was used as a dissolution-permeation flux (J
resultsFor all SL-E drugs, the food effect on Fa was theoretically predicted to be 1.2, irrespective of bile micelle solubilization (FaSSIF/FeSSIF: bosentan (2.1), fidaxomicin (2.3), pranlukast (9.1), and rifaximin (3.5)). Theoretically, an increase in solubility by bile micelles is counterbalanced by a decrease in effective permeability (P
conclusionFaRLS appropriately predicted the food effect for the SL-E drugs. The mechanism was experimentally confirmed by μFlux.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.